140 Intracoastal Pointe Drive, Suite 404
Jupiter, Florida 33477-5094 USA
C1 Technology Solutions
Enable rapid gene discovery. Accelerate product development. Bring gene products to market faster. Dyadic’s proprietary C1 technology is used for gene discovery, host optimization, large-scale manufacturing, and the creation of new products for diverse markets such as animal feed, pulp and paper, food, beverages, textiles, biofuels, biochemicals and biopharmaceuticals.
Develop advanced dependable bioenergy solutions. Identify novel enzymes that convert biomass into fermentable sugars for use in producing biofuels. Bring more cost-effective alternative fuel solutions to market faster. Dyadic’s C1 technology creates new development opportunities, through licensing arrangements and partnerships.
Break the bottlenecks in your genomic research and development programs. Accelerate product development. Improve production yields. Dyadic is interested in forming strategic partnerships to discover biomaterials, lower your costs, develop new products and bring them to market quickly.
Go from gene discovery to commercial manufacturing using the same host microorganism. Use Dyadic enzymes for large-scale production of innovative products. Dyadic delivers the C1 platform technology and more than 50 enzyme products to customers worldwide.
Welcome to Dyadic. We are a global biotechnology company with patented and proprietary technologies that are used to discover, develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic’s C1 platform technology enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. Dyadic leverages the value of its technologies through licensing arrangements and other collaborations with third parties who receive the benefits of producing and using the proteins these technologies help produce. LEARN MORE
May 16, 2013
Dyadic First Quarter 2013 Conference Call Replay Click Here
May 15, 2013
Dyadic International Reports First Quarter 2013 Financial Results Read More
May 15, 2013
BASF and Dyadic International Enter Into a Research and License Agreement Read More
May 7, 2013
Danai Brooks Joins Dyadic International as Chief Operating Officer Read More
April 26, 2013
Wall Street Transcript Interview with the Founder, Chairman, President and CEO: Dyadic International (DYAI) Read More
World Biotechnology Congress
June 3 - 6, 2013 Boston, MA
Mark Emalfarb Speaking Thursday, June 6, 2013 11:20 a.m. - 11:40 a.m. Read More
World Congress on Industrial Biotechnology
June 16 - 19, 2013 Montreal, Canada
Mark Emalfarb Speaking Tuesday, June 18, 2013 - 10:30 am-12:00 pm Read More